Fidelity Investments
MLYS icon

Fidelity Investments’s Mineralys Therapeutics MLYS Stock Holding History

Fidelity Investments’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132M Sell
4,861,104
-196,405
-4% -$5.76M 0.01% 1051
2025
Q4 		$184M Buy
5,057,509
+2,986,254
+144% +$120M 0.01% 901
2025
Q3 		$78.5M Buy
2,071,255
+1,766,369
+579% +$38.2M ﹤0.01% 1280
2025
Q2 		$4.13M Buy
304,886
+128
+0% +$1.85K ﹤0.01% 2237
2025
Q1 		$4.84M Buy
304,758
+574
+0.2% +$6.6K ﹤0.01% 2157
2024
Q4 		$3.74M Buy
304,184
+426
+0.1% +$5.57K ﹤0.01% 2256
2024
Q3 		$3.68M Buy
303,758
+32,663
+12% +$395K ﹤0.01% 2217
2024
Q2 		$3.17M Buy
271,095
+269,551
+17,458% +$3.39M ﹤0.01% 2213
2024
Q1 		$19.9K Sell
1,544
-29,743
-95% -$367K ﹤0.01% 4021
2023
Q4 		$269K Sell
31,287
-1,157,366
-97% -$9.09M ﹤0.01% 2863
2023
Q3 		$11.3M Buy
1,188,653
+457,815
+63% +$5.97M ﹤0.01% 1790
2023
Q2 		$12.5M Buy
730,838
+730,209
+116,090% +$10.9M ﹤0.01% 1791
2023
Q1 		$9.85K Buy
+629
New +$10.6K ﹤0.01% 4136

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments's MLYS Position: Q1 2026 in Review

Fidelity Investments reduced its Mineralys Therapeutics (MLYS) stake by 3.9% in Q1 2026, selling an estimated $5.76M and leaving 4,861,104 shares worth $132M. The position accounts for 0.01% of the portfolio, ranked #1051.

Fidelity Investments first reported a position in MLYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $184M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Fidelity Investments held 4,861,104 shares of Mineralys Therapeutics worth $132M as of Q1 2026.
  • Fidelity Investments sold 196,405 Mineralys Therapeutics shares in Q1 2026, an estimated $5.76M.
  • Mineralys Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #1051 holding.
  • Fidelity Investments first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Fidelity Investments's Mineralys Therapeutics position peaked at $184M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.